Kara Langer
About Kara Langer
Kara Langer serves as the Associate Director of Clinical Operations at BridgeBio, bringing extensive experience in clinical trial project management. She has a strong background in improving research processes for rare disease patients and has held various roles in reputable organizations throughout her career.
Work at BridgeBio
Kara Langer currently serves as the Associate Director of Clinical Operations at BridgeBio. She has been in this role since 2023, contributing to the company's efforts in advancing clinical research. BridgeBio focuses on developing innovative therapies for patients with rare diseases, aligning with Langer's commitment to improving clinical research processes.
Previous Experience in Clinical Operations
Prior to her role at BridgeBio, Langer worked at Veristat as a Senior Project Manager from 2021 to 2023 and as a Project Manager II from 2018 to 2021. She also held various positions at Covance, including Project Manager and Associate Project Manager, from 2014 to 2018. Her career trajectory reflects a consistent rise in responsibilities within clinical operations and project management.
Education and Expertise
Kara Langer holds a Bachelor of Science (B.S.) degree in Natural Sciences with a focus on Genetics from the University of Wisconsin-Madison, where she studied from 2002 to 2006. Additionally, she studied Thai Studies, Economics, and Anthropology at Thammasat University, participating in a Study Abroad Program in 2005.
Background in Research and Management
Langer began her career as a Student Research Assistant at McArdle Laboratory for Cancer Research, where she worked from 2003 to 2006. She also gained experience in retail management as an Assistant Manager at White House Black Market from 2007 to 2008. Her diverse background has contributed to her extensive experience in full-service clinical trial project management.
Focus on Rare Disease Research
Kara Langer has a strong focus on improving clinical research processes to benefit rare disease patients and their families. This commitment is evident in her work at BridgeBio and throughout her career in clinical operations, where she has consistently aimed to enhance the effectiveness of clinical trials.